4.4 Review

Myostatin and Sarcopenia: Opportunities and Challenges - A Mini-Review

期刊

GERONTOLOGY
卷 60, 期 4, 页码 289-293

出版社

KARGER
DOI: 10.1159/000356740

关键词

Aging; Frailty; Skeletal muscle; Atrophy; Growth and differentiation factor; Drug discovery; Obesity; Diabetes

资金

  1. Mayo Clinic Center for Cell Signaling in Gastroenterology [NIDDK P30DK084567]
  2. Mayo Clinic

向作者/读者索取更多资源

The progressive loss of skeletal muscle mass, strength and/or function with advancing age, termed sarcopenia, poses a major threat to independence and quality of life. Therefore, there is significant merit in better understanding the biology of sarcopenia and developing therapeutic interventions to prevent, slow or reverse its progression. Since the discovery of nnyostatin, a potent negative regulator of growth that is highly enriched in skeletal muscle, there has been great interest in it as a potential mediator of sarcopenia as well as a therapeutic target. The complex biology of myostatin, the promise of myostatin inhibition as an effective means to counter sarcopenia, and the challenges facing its clinical translation are reviewed herein. (C) 2014 S. Karger AG, Basel

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据